GlassScriptPhysician profile
Mohsen Khan
NPI 1316203367
$10,060.14
in general payments reported to CMS, 2019-2025
36 companies · $1,275 in 2025
The $1,275 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $796 · 2020: $817 · 2021: $1,602 · 2022: $2,167 · 2023: $2,366 · 2024: $1,038 · 2025: $1,275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,663 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,662.82 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $2,465.55 | 2020-2023 | |
| Abbvie INC. | $1,915.73 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $946.47 | 2019-2025 | Trulance, Xifaxan, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $836.53 | 2019-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $557.23 | 2022-2025 | Tremfya, Stelara, Simponi |
| Allergan, INC. | $550.39 | 2019-2020 | |
| Celgene Corporation | $382.95 | 2021-2023 | Zeposia |
| Ironwood Pharmaceuticals, INC | $184.81 | 2020-2025 | Linzess |
| Endogastric Solutions, INC | $170.33 | 2023 | Esophyx |
| Ardelyx, INC. | $159.19 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $149.53 | 2022-2025 | |
| Olympus America INC. | $148.07 | 2024 | Endocapsule Recorder, Visiglide, Hanarostent Esophagus Tts(Ccc) |
| Conmed Corporation | $144.74 | 2022 | |
| Braintree Laboratories, INC. | $128.69 | 2019-2024 | Suflave, Sutab |
| Celltrion USA INC. | $120.24 | 2025 | Vegzelma |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $118.88 | 2019-2024 | |
| Aimmune Therapeutics, INC. | $112.45 | 2024-2025 | Zenpep |
| Merck Sharp & Dohme LLC | $101.37 | 2021-2023 | Dificid |
| Vivus LLC | $98.01 | 2022-2025 | Pancreaze |
| Evoke Pharma, INC. | $90.47 | 2021-2024 | Gimoti |
| Medtronic, INC. | $81.70 | 2021 | |
| Madrigal Pharmaceuticals | $79.19 | 2025 | Rezdiffra |
| Ferring Pharmaceuticals INC. | $74.51 | 2019-2024 | Rebyota |
| Romark Laboratories, Lc | $67.25 | 2020 | |
| Shionogi INC | $66.75 | 2019-2020 | |
| Lilly USA, LLC | $60.06 | 2024 | Omvoh |
| Qol Medical, LLC | $50.14 | 2024-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $37.72 | 2024 | Dupixent |
| Phathom Pharmaceuticals, INC. | $35.90 | 2025 | Voquezna |
| Sandoz INC. | $29.14 | 2023-2024 | Hyrimoz |
| Novo Nordisk INC | $27.93 | 2025 | Wegovy |
| Pfizer INC. | $18.22 | 2025 | |
| Capsovision, INC. | $15.91 | 2023 | Capsocam Plus |
| Shire North American Group INC | $15.76 | 2019 | |
| Intercept Pharmaceuticals, INC. | $13.96 | 2020 | |
| Echosens North America, INC. | $4.37 | 2025 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohsen Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.